Taraxasterol suppresses the growth of human liver cancer by upregulating Hint1 expression

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Liver cancer remains a significant global health challenge with limited effective treatments.
• Histidine triad nucleotide-binding protein 1 (Hint1) is a known tumor suppressor whose reduced expression is linked to various cancers.
• The therapeutic potential of Taraxasterol, particularly its mechanisms against liver cancer, requires further elucidation.

Purpose of the Study:

• To investigate the effects of Taraxasterol on human liver cancer cell proliferation, cell cycle, and apoptosis.
• To explore the underlying molecular mechanisms of Taraxasterol's action, focusing on Hint1 expression and its downstream targets.
• To evaluate the in vivo efficacy and safety of Taraxasterol in a mouse model of liver cancer.

Main Methods:

• In vitro studies using human liver cancer cell lines (e.g., HepG2) and non-tumor hepatocytes.
• Assessment of cell proliferation, cell cycle distribution (G0/G1 arrest), and apoptosis assays.
• Analysis of gene and protein expression levels (Hint1, Bax, Bcl2, cyclin D1) and promoter methylation.
• In vivo efficacy study using subcutaneous liver cancer xenografts in BALB/c mice, with safety assessments.

Main Results:

• Taraxasterol significantly suppressed liver cancer cell proliferation and induced G0/G1 cell cycle arrest and apoptosis.
• Taraxasterol upregulated Hint1 and Bax, while downregulating Bcl2 and cyclin D1 expression in liver cancer cells.
• Demethylation of the Hint1 promoter region was observed following Taraxasterol treatment.
• Hint1 silencing abrogated Taraxasterol's effects, while Bax silencing or Bcl2/cyclin D1 overexpression partially mitigated them.
• In vivo, Taraxasterol inhibited tumor growth without adverse effects on body weight or major organ morphology in mice.

Conclusions:

• Taraxasterol demonstrates potent anti-liver cancer activity by inhibiting proliferation and inducing apoptosis.
• The mechanism involves the upregulation of Hint1 expression, likely through promoter demethylation, influencing downstream targets like Bax, Bcl2, and cyclin D1.
• Taraxasterol presents a promising therapeutic candidate for human liver cancer treatment.